Advertisement

Are Glutamate/Aspartate Antagonists Protective in Cerebral Ischemia?

  • John C. Drummond

Abstract

The dicarboxylic amino acids glutamate and aspartate are abundant excitatory neurotransmitters in the mammalian nervous system [1]. Glutamate and aspartate and perhaps other endogenous “excitotoxic” substances, eg., quinolinic acid [2,3] have been implicated as contributory or primary causative agents of neuronal injury in several neuropathologic processes including epilepsy [4], Huntington’s disease [5,6], Alzheimer’s disease [7] olivo-pontocerebellar atrophy [8], the degenerative changes associated with hypoglycemia [9], aging, and hypoxic-ischemic injury [10]. The relevance of excitatory amino acids (EAA’s) to hypoxic-ischemic neural injury will be the focus of this presentation. However, an overview of EAA physiology is a necessary back-ground for the discussion.

Keywords

Middle Cerebral Artery Occlusion Excitatory Amino Acid NMDA Antagonist Quinolinic Acid Cereb Blood Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fagg GE, Foster AC (1983) Amino acid neurotransmitters and their pathways in the mammalian central nervous system Neuroscience 9: 701–719Google Scholar
  2. 2.
    Schwarcz R, Whetsell WO, Mangano RM (1983) Quinolinic acid: An endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219: 316–318PubMedCrossRefGoogle Scholar
  3. 3.
    Schwarcz R, Meldrum B (1985) Excitatory amino acid antagonists provide a therapeutic approach to neurological disorders. Lancet II: 140–143Google Scholar
  4. 4.
    Greenamyre JT (1986) The role of glutamate in neurotransmission and in neurologic disease. Arch Neurol 43: 1058–1063PubMedCrossRefGoogle Scholar
  5. 5.
    Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature 321: 168–171PubMedCrossRefGoogle Scholar
  6. 6.
    Koh J-Y, Choi DW (1988) Cultured striatal neurons containing NADPH-diaphorase or acetylcholinesterase are selectively resistant to injury by NMDA receptor agonists. Brain Res 446: 374–378PubMedCrossRefGoogle Scholar
  7. 7.
    Greenamyre JT, Penney JB, Young AB, D’Amato CJ, Hicks SP, Shoulson I (1985) Alterations in L-glutamate binding in Alzheimer’s and Huntington’s diseases. Science 227: 1496–1499PubMedCrossRefGoogle Scholar
  8. 8.
    Plaitakis A, Berl S, Yahr M (1982) Abnormal glutamate metabolism in an adult-onset degenerative neurological disorder. Science 216: 193–196PubMedCrossRefGoogle Scholar
  9. 9.
    Wieloch T (1985) Hypoglycemia-induced neuronal damage prevented by an Nmethyl-D-aspartate antagonist. Science 230: 681–683PubMedCrossRefGoogle Scholar
  10. 10.
    Rothman SM, Olney JW (1986) Glutamate and the pathophysiology of hypoxicischemic brain damage. Ann Neurol 19: 105–111PubMedCrossRefGoogle Scholar
  11. 11.
    Jahr CE, Stevens CF (1987) Glutamate activates multiple single channel conductances in hippocampal neurons. Nature 325: 522–525PubMedCrossRefGoogle Scholar
  12. 12.
    Greenamyre JT, Olson JMM, Penney JB, Young AB (1985) Autoradiographic characterization of N-methyl-D-aspartate, quisqualate and kainate sensitive glutamate binding sites. J Pharmacol Exp Ther 233: 254–263PubMedGoogle Scholar
  13. 13.
    Monaghan DT, Holets VR, Toy DW, Cotman CW (1983) Anatomical distributions of four pharmacological distinct H-L-glutamate binding sites. Nature 306: 175–179CrossRefGoogle Scholar
  14. 14.
    Cha J-HJ, Greenamyre T, Nielsen EO, Penney JB, Young AB (1988) Properties of quisqualate-sensitive L-[3H] glutamate binding sites in rat brain as determined by quantitative autoradiography. J Neurochem 51 (2): 469–478PubMedCrossRefGoogle Scholar
  15. 15.
    Robinson MB, Coyle JT (1987) Glutamate and related acidic excitatory neurotransmitters: From basic science to clinical application. FASEB J 1: 446–455PubMedGoogle Scholar
  16. 16.
    Collingridge GL, Bliss TVP (1987) NMDA receptors—their role in long-term potentiation. Trends Neurosci 10: 288–292CrossRefGoogle Scholar
  17. 17.
    Foster AC, Gill R, Kemp JA, Woodruff GN (1987) Systemic administration of MK-801 prevents N-methyl-D-aspartate-induced neuronal degeneration in rat brain. Neurosci Lett 76: 307–311PubMedCrossRefGoogle Scholar
  18. 18.
    Olney JW, Fuller T, deGubareff T (1979) Acute dendrotoxic changes in the hippo-campus of kainate-treated rats. Brain Res 176: 91–100PubMedCrossRefGoogle Scholar
  19. 19.
    Choi DW (1985) Glutamate neurotoxicity in cortical cell culture is calcium-dependent. Neurosci Lett 58: 293–297PubMedCrossRefGoogle Scholar
  20. 20.
    Choi DW (1987) Ionic dependence of glutamate neurotoxicity. J Neurosci 7: 369–379PubMedGoogle Scholar
  21. 21.
    Swan JH, Evans MC, Meldrum BS (1988) Long-term development of selective neuronal loss and the mechanism of protection by 2-amino-7-phosphonoheptanoate in a rat model of incomplete forebrain ischaemia. J Cereb Blood Flow Metab 8: 64–78PubMedCrossRefGoogle Scholar
  22. 22.
    Greenfield’s Neuropathology, 4th edn (1984) Adams JH, Corsellis JAN, Duchen LW (eds) Wiley, New York, pp 131–132Google Scholar
  23. 23.
    Benveniste H, Dreyer J, Schousboe A, Diemer NH (1984) Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 43: 1369–1374PubMedCrossRefGoogle Scholar
  24. 24.
    Choi DW, Maulucci-Gedde M, Kriegstein AR (1987) Glutamate neurotoxicity in cortical cell culture. J Neurosci 7: 357–368PubMedGoogle Scholar
  25. 25.
    Rothman SM (1984) Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J Neurosci 4: 1884–1891PubMedGoogle Scholar
  26. 26.
    Choi DW, Koh J, Peters S (1988) Pharmnacology of glutamate neurotoxicity in cortical cell culture: Attenuation by NMDA antagonists. J Neurosci 8: 185–196PubMedGoogle Scholar
  27. 27.
    Robinson MB, Anderson KD, Koerner JF (1984) Kynurenic acid as an antagonist of hippocampal excitatory transmission. Brain Res 309: 119–126PubMedCrossRefGoogle Scholar
  28. 28.
    Simon RP, Swan JH, Griffiths T, Meldrum BS (1984) Blockade of N-Methyl-DAspartate receptors may protect against ischemic damage in the brain. Science 226: 850–852PubMedCrossRefGoogle Scholar
  29. 29.
    Block GA, Pulsinelli WA (1987) Excitatory amino acids receptor antagonists: Failure to prevent ischemic neuronal damage. J Cereb Blood Flow Metab 7 (Suppl 1): S149Google Scholar
  30. 30.
    Diemer NH, Sandberg M, Jorgensen MB, Benveniste H (1989) Ischemia-induced release of glutamate in the hippocampal CAl region is decreased after removal of the excitatory input from the CA3. J Cereb Blood Flow Metab 9 (Suppl 1): S747Google Scholar
  31. 31.
    Wieloch T, Lindwall O, Blomqvist P, Gage FH (1985) Evidence for amelioration of ischaemic neuronal damage in the hippocampal formation by lesions of the perforant path. Neurosci Res 7: 24–26Google Scholar
  32. 32.
    Johansen FF, Jorgensen MB, Diemer NH (1987) Ischemia-induced delayed neuronal death in the CA-1 hippocampus is dependent on intact glutamatergic innervation. In: Hicks M, Lodge D, McLennan H (eds) Excitatory amino acid transmission. Liss, New York, pp 245–248Google Scholar
  33. 33.
    Pulsinelli WA (1988) CNS excitation-inhibition and ischemic injury to neurons. Anesthesiology Review 15: 50–51Google Scholar
  34. 34.
    Choi DW, Peters S, Viseskul V (1987) Dextrorphan and levorphanol selectively block N-methyl-D-aspartate receptor-mediated neurotoxicity on cortical neurons. J Pharmacol Exp Ther 242: 713–720PubMedGoogle Scholar
  35. 35.
    Goldberg MP, Pham P-C, Choi DW (1987) Dextrorphan and dextromethorphan attenuate hypoxic injury in neuronal culture. Neurosci Lett 80: 11–15PubMedCrossRefGoogle Scholar
  36. 36.
    Kemp JA, Foster AC, Wong HF (1987) Non-competitive antagonists of excitatory amino acid receptors. Trend Neurosci 10: 295–298CrossRefGoogle Scholar
  37. 37.
    Steinberg GK, George CP, DeLaPaz R, Shibata DK, Gross T (1988) Dextromethorphan protects against cerebral injury following transient focal ischemia in rabbits. Stroke 19 (9): 1112–1118PubMedCrossRefGoogle Scholar
  38. 38.
    Kochhar A, Zivin JA, Lyden PD, Mazzarella V (1988) Glutamate antagonist therapy reduces neurologic deficits produced by focal central nervous system ischemia. Arch Neurol 45: 148–153PubMedCrossRefGoogle Scholar
  39. 39.
    Ozyurt E, Graham DI, Woodruff GN, McCulloch J (1988) Protective effect of the glutamate antagonist, MK-801 in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab 8: 138–143PubMedCrossRefGoogle Scholar
  40. 40.
    Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J (1988) Focal cerebral ischemia in the cat: Treatment with the glutamate antagonist MK-801 in the cat after induction of ischemia. J Cereb Blood Flow Metab 8: 757–762PubMedCrossRefGoogle Scholar
  41. 41.
    Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J (1988) The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol 24: 543–551PubMedCrossRefGoogle Scholar
  42. 42.
    Michenfelder JD, Lanier WL, Scheithauer BW, Perkins WJ, Shearman GT, Milde JH (1989) Evaluation of the glutamate antagonist dizocilipine maleate (MK-801) on neurologic outcome in a canine model of complete cerebral ischemia: Correlation with hippocampal histopathology. Brain Res 481: 229–234CrossRefGoogle Scholar
  43. 43.
    Fleischer JE, Tateishi A, Drummond JC, Scheller MS, Zornow MH, Grafe MR, Zornow MH, Shearman GT, Shapiro HM (1989) MK-801, an excitatory amino acid antagonist, does not improve neurologic outcome following cardiac arrest in cats. J Cereb Blood Flow Metab 9: 795–804PubMedCrossRefGoogle Scholar
  44. 44.
    Lanier WL, Perkins WJ, Ruud B, Milde JH, Michenfelder JD (1988) The effect of the excitatory amino acid antagonist MK-801 on neurologic function following complete cerebral ischemia in primates. Anesthesiology 69: A846CrossRefGoogle Scholar
  45. 45.
    Sterz F, Leonov Y, Safar P, Radovsky, Stezoski SW, Reich H, Shearman GT, Greber TF (1989) Effect of excitatory amino acid receptor blocker MK-801 on overall, neurologic, and morphologic outcome after prolonged cardiac arrest in dogs. Anesthesiology 71: 907–918PubMedCrossRefGoogle Scholar
  46. 46.
    Gill R, Foster AC, Woodruff GN (1987) Systemic administration of MK-801 protects against ischemia-induced hippocampal neuro-degeneration in the gerbil. J Neurosci 7: 3343–3349PubMedGoogle Scholar
  47. 47.
    Lawrence JJ, Fuller TA, Olney JW (1987) MK-801 and PCP protect against ischemic neuronal degeneration in the gerbil hippocampus. Soc Neurosci Abstr 13: 1079Google Scholar
  48. 48.
    Boast CA, Gerhardt SC, Janak P (1987) Systemic AP7 reduces ischemia brain damage in gerbils. In: Hicks TP, Lodge D, McLennan-H (eds) Excitatory amino acid transmission. Liss, New York, pp 249–252Google Scholar
  49. 49.
    Boast CA, Gerhardt SC, Pastor G (1988) The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils. Brain Research 442: 345–348PubMedCrossRefGoogle Scholar
  50. 50.
    Siesjö BK, Bengtsson F (1989) Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: A unifying hypothesis. J Cereb Blood Flow Metab 9: 127–140PubMedCrossRefGoogle Scholar
  51. 51.
    Wieloch T, Gustafson I, Westerberg E (1989) The NMDA antagonist, MK-801, is cerebro-protective in situations where some energy production prevails but not under conditions of complete energy deprivation. J Cereb Blood Flow Metab 9 (Suppl 1): S6Google Scholar
  52. 52.
    Buchan AM, Pulsinelli WA (1990) Hypothermia but not N-Methyl-D-Aspartate antagonist MK-801 attenuates neuronal damage in gerbils subjected to transient global ischemia. J Neurosci 10: 311–316.PubMedGoogle Scholar
  53. 53.
    Wong EHF, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL (1986) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 83: 7104–7108PubMedCrossRefGoogle Scholar
  54. 54.
    Perkins WJ, Lanier WL, Ruud B, Milde JH, Michenfelder JD (1988) The cerebral and systemic effects of the excitatory amino acid receptor antagonist MK-801 in dogs: Modification by prior complete cerebral ischemia. Anesthesiology 69: A589CrossRefGoogle Scholar
  55. 55.
    Park CK, Nehls DG, Teasdale GM, McCulloch J (1989) Effect of the NMDA antagonist MK-801 on local cerebral blood flow in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 9: 617–622PubMedCrossRefGoogle Scholar
  56. 56.
    Boast CA, Pastor G (1987) Characterization of motor activity patterns induced by N-methyl-D-aspartate antagonists in gerbils. Pharmacol Biochem Behav 27: 553–557PubMedCrossRefGoogle Scholar
  57. 57.
    Koek W, Woods JH, Winger GD (1988) MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and Rhesus monkeys. Pharmacol Exp Ther 245: 969–974Google Scholar
  58. 58.
    Fagg GE (1987) Phencyclidine and related drugs bind to the activated N-methyl-Daspartate receptor-channel complex in rat brain membranes. Neurosci Lett 76: 221–227PubMedCrossRefGoogle Scholar
  59. 59.
    Koek W, Woods JH, Mattson MV, Jacobson AE, Mudar PJ (1987) Excitatory amino acid antagonists induce a phencyclidine-like catalepsy in pigeons: Structure-activity studies. Neuropharmacology 26: 1261–1265PubMedCrossRefGoogle Scholar
  60. 60.
    Bowery NG, Wong EHF, Hudson AL (1988) Quantitative autoradiography of [3H]MK-801 binding sites in mammalian brain. Br J Pharmacol 93: 944–954PubMedGoogle Scholar
  61. 61.
    Davis DW, Mans AM, Biebuyck JF, Hawkins RA (1988) The influence of ketamine on regional brain glucose use. Anesthesiology 69: 199–205PubMedCrossRefGoogle Scholar
  62. 62.
    Bennett DA, Bernard BS, Amrick CL, Wilson DE, Hutchinson AJ (1987) The pharmacological profile of an N-methyl-D-aspartate (NMDA) antagonist, CGS 19755. Soc Neurosci Abstr 13: 1561Google Scholar
  63. 63.
    Scheller MS, Zornow MH, Shearman GT, Greber TF (1989) Non-competitive Nmethyl-D-Aspartate receptor blockade profoundly reduces volatile anesthetic requirement in rabbits. Neuropharmacology: 28: 677–681PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1991

Authors and Affiliations

  • John C. Drummond
    • 1
  1. 1.Department of AnesthesiologyUniversity of CaliforniaSan DiegoUSA

Personalised recommendations